Intercell AG and CSL Ltd. sign Exclusive Agreement for Marketing and Distribution of Japanese Encephalitis Vaccine
In order to optimally market the vaccine in Australia where the disease is endemic, Intercell has been seeking for a strong local strategic partner. Under the terms of this agreement CSL Ltd. receives the sole and exclusive marketing and distribution rights of Intercell´s novel prophylactic vaccine against Japanese encephalitis in Australia, New Zealand, Papua New Guinea and Pacific Islands.
Intercell is planning to market the product independently from this agreement with CSL Ltd. in the United States and Europe targeting the travelers and armed forces market to replace current suboptimal vaccines produced on mouse brain. The production of the vaccine will be performed at Intercell´s facility in Livingston, Scotland.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.